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The quality of life in patients after peripheral
bypass surgery deteriorates at long-term follow-up
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Frans L. Moll, MD, PhD,a and Ale Algra, MD, PhD,c,d Utrecht, The Netherlands
Objective: We aimed to study the long-term development of health-related quality of life (HR-QoL) in patients with
peripheral arterial disease after they underwent peripheral bypass surgery and to evaluate the influence of adverse vascular
events that occurred during follow-up.
Methods: We compared current HR-QoL scores with previous measurements in patients who participated in the Dutch
Bypass and Oral Anticoagulants or Aspirin (BOA) Study between 1995 and 1998 after they underwent infrainguinal
bypass surgery. Patients from six centers that contributed most to the Dutch BOA Study (n  482) were followed up
retrospectively from 1995 up to 2009.
Results:At amean follow-up of 11 years since BOA randomization, 165 of the 482 patients were alive of whom 123 (75%)
completed the EQ-5D and RAND-36 questionnaires. Fifty-three patients completed the questionnaires three times: at
BOA entry, at BOA close-out, and at BOA long-term follow-up. In these patients the HR-QoL scores decreased over
time, especially for the physical health dimension. In comparison with the general population, matched for age and
gender, the HR-QoL scores at both BOA entry and long-term follow-up were substantially lower, even if the patient’s
graft was patent and no other vascular events had occurred. The occurrence of an adverse vascular event worsened the
physical health state further.
Conclusions: The physical HR-QoL in patients with peripheral arterial disease (PAD) after peripheral bypass surgery was
highly impaired, independent of graft patency, and deteriorated further over time. An adverse vascular event worsened
the physical health state and underlined the importance of atherosclerotic risk management as well as stimulation of




























mGenerally, peripheral bypass surgery is performed to
improve walking distance, diminish symptoms of intermit-
tent claudication, or increase limb salvage in case of critical
limb ischemia, a grave condition of peripheral arterial dis-
ease (PAD).1 In clinical practice, important outcome mea-
sures of bypass surgery are the technical and clinical success
rates. For patients, treatment success is merely determined
by their perception of change in physical, psychological,
and social well-being after revascularization. Indeed, clini-
cally successful bypass surgery was found to significantly
improve the health-related quality of life (HR-QoL) in
patients with critical limb ischemia up to 1 year after
intervention,2 whereas symptomatic graft-related events,
lower limb amputation, and ischemic events that occurred
within 21months or less after revascularization reduced the
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doi:10.1016/j.jvs.2010.09.021R-QoL substantially.2,3 Besides lower limb amputation,
atients with PAD are also at high risk of myocardial
nfarction, stroke, and major bleeding.4,5 To determine the
ong-term HR-QoL after peripheral bypass surgery, we
ssessed the present HR-QoL in PAD patients who under-
ent peripheral bypass surgery between 1995 and 1998.
hese results were compared with HR-QoL scores ob-
ained no longer than 2 years after bypass surgery. Our
econd aim was to evaluate the influence of adverse vascular
vents that occurred after peripheral bypass surgery on the
R-QoL at long-term follow-up.
ETHODS
Study population. The present study population was
ased on the Dutch Bypass and Oral Anticoagulants or
spirin (BOA) Study.6 This multicenter randomized trial
ompared the effects of treatment with oral anticoagulants
r aspirin on preventing bypass occlusion and ischemic
omplications in patients who underwent infrainguinal by-
ass surgery. Full details of the Dutch BOA Study have
een published elsewhere.6 We conducted a retrospective
ong-term follow-up of the Dutch BOA Study. A sample of
82 patients from six centers that contributed the largest
umber of patients to the Dutch BOA Study was fol-
owed-up from 1995 to 2009. This sample size was based
n the primary outcome event rate of the Dutch BOA
tudy. At an extended follow-up, we expected over 50% of
he 482 patients to have experienced a primary outcome
vent allowing for the development of valid prediction
odels for an additional study. At the time of our approach






















































JOURNAL OF VASCULAR SURGERY
March 2011644 van Hattum et alpatients were still alive and included in the present study on
HR-QoL. Their scores were set off against HR-QoL scores
obtained earlier, between November 1995 and April 1998
over a mean follow-up of 26 months (range, 1 day to 45
months), in 1001 patients from the Dutch BOA Study.3
All patients who participated in the Dutch BOA Study
and the present study gave written informed consent.
HR-QoL assessment. All 165 patients were sent the
EuroQoL 5 Dimensions (EQ-5D) and the RAND-36
questionnaires by postal mail. Nonresponders were sent a
reminder or were contacted by telephone. Incomplete
questionnaires were returned to the patients for comple-
tion. If necessary, the missing questions or questionnaires
of participants who required help were completed by tele-
phone call.
The EQ-5D7 and the RAND-368,9 measure the ge-
neric quality of life and are designed for self-completion by
the respondent. Both are valid and reliable question-
naires,10–15 and have shown to be suitable for perceived
health assessment in patients with PAD.16–21
The EQ-5D consists of five dimensions concerning
mobility, self-care, usual activities, pain or discomfort, and
anxiety or depression.7,22 Each dimension has three levels:
(1) no problems; (2) some or moderate problems; and (3)
extreme problems. The combination of each selected level
per dimension results in a unique EQ-5D health state,
which refers to a weighted health state index that ranges
from 0.0 (death) to 1.0 (perfect health) developed by the
EuroQol Group itself.7,22 In addition, the EQ-5D includes
the Visual Analogue Scale (VAS), which records the self-
related health status on a vertical graduated scale from 0
(worst imaginable health state) to 100 (best imaginable
health state).
The RAND-36 consists of 36 questions with standard-
ized response choices8,9 and refers to eight health dimen-
sions: physical functioning, role of limitations due to phys-
ical health problems, bodily pain, general health
perceptions, vitality, social functioning, role of limitations
due to emotional problems, and mental health. Each di-
mension is represented on a scale from 0 to 100, with a high
score defining a favorable health state. The scores of the
first four and last four scales are aggregated into a physical
and a mental component summary score, respectively.
Collection of outcome events. The long-term fol-
low-up data of the 482 selected patients were collected
retrospectively from the last patient visit of the Dutch BOA
Study in April 1998 until August 2009 in a stepwise man-
ner. The patient, the patient’s attending vascular surgeon,
and the patient’s general practitioner were contacted to
obtain information on outcome events. In case the patient
was deceased, relatives or acquaintances were approached
for follow-up data. The municipality register was queried
about the last known residence if the patient had moved. If
the patient, the patient’s relatives, or acquaintances did not
respond, the registry office was contacted to inform
whether the patient was deceased and when. Data on
outcome events, which occurred during the Dutch BOA
Study between 1995 and 1998, had already been col- Sected prospectively at follow-up visits at 3 and 6 months
fter bypass surgery and every 6 months thereafter until
pril 1998.
Registered outcome events were primary bypass occlu-
ion, nonfatal myocardial infarction, nonfatal ischemic
troke, major amputation, minor and major bleeding, and
eath. The definition of each ischemic outcome event has
een published in full detail elsewhere.6 The definition of
ajor bleeding corresponded with the criteria of the Inter-
ational Society on Thrombosis and Haemostasis,23 and
as also been published in full detail elsewhere.24 Each
ecorded outcome event was adjudicated and classified by a
anel consisting of a vascular surgeon, a clinical epidemiol-
gist, a neurologist, and a cardiologist from the University
edical Center Utrecht, The Netherlands. Each specialist
djudicated and classified each outcome event individually.
ny discrepancy was resolved plenary by discussion and
ocumented in a logbook to ensure consistent adjudication
nd classification of new outcome events.
Data analysis. Descriptive statistics were used to com-
are patient characteristics between responders and nonre-
ponders at follow-up. Differences in characteristics with a
ichotomous outcome were reported as relative risks with
orresponding 95% confidence intervals (95% CIs) and
oncomitant P values. Characteristics with a continuous
utcome were reported as mean differences with 95% CIs
nd concomitant P values, which were derived from an
ndependent samples two-sided Student t-test.
The short-term HR-QoL scores obtained at BOA in-
lusion and the long-term HR-QoL scores obtained at
OA follow-up were described as means with a standard
eviation (SD) and compared with the norm HR-QoL
cores of the Dutch population9,25 at the same age or
ender. In 1992, the normative data for the RAND-36
ere collected from 1063 Dutch respondents with an age
f 18 years or older.9 Repeated measurements at 2 or at 6
onths in a random sample showed a sufficient external
alidity of their results. Between April 2000 and January
002, 9685Dutch respondents aged 18 years or older filled
ut the EQ-5D questionnaire every 3 months within 1
ear.25 These figures were weighted for gender, age, and
rbanization to make them representative of the Dutch
opulation. Comparisons with the HR-QoL scores of the
utch population were reported as mean differences with
orresponding 95% CI only without concomitant P values
s we could not provide precise P values but only crude
stimations, because we do not have the raw data of the
utch population in question.
Further, the long-termHR-QoL scores were compared
etween patients with and without adverse vascular events.
ifferences were reported as mean differences with corre-
ponding 95% CI and concomitant P values derived from
n independent samples two-sided Student t-test.
Finally, a separate comparison was done for HR-QoL
cores that were obtained thrice in the same patient; first at
OA inclusion, then at the last patient visit in BOA, and
nally at long-term follow-up between 2005 and 2009.
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Volume 53, Number 3 van Hattum et al 645reported as mean differences with corresponding 95% CIs
and concomitant P values derived from a paired two-sided
Student t-test.
RESULTS
Participants. Between 2005 and 2009, the long-term
follow-up of the Dutch BOA Study was done in 482
patients (Fig 1). Of the 165 patients alive at long-term
follow-up, 123 patients completed the HR-QoL-question-
naires resulting in a response rate of 75% (Fig 2). For the
remaining 42 patients, no HR-QoL data were obtained at
long-term follow-up, because 5 were lost to follow-up, 18
refused participation, 13 patients were not able to fill out
the questionnaire because it was too exhausting at their
advanced age, 5 patients had dementia, and 1 patient had
experienced a stroke. The 123 responders were younger
than the 42 nonresponders (62 and 67 years, respectively)
and had fewer transient ischemic attacks or strokes at BOA
study-entry (4% and 17%, respectively; Table I). No other
statistically significant differences were seen between re-
sponders and nonresponders. The mean follow-up of the
123 responders and the 42 nonresponders since random-
ization in BOA was 11 years.
Of the 123 responders, 53 patients completed the
HR-QoL-questionnaires three times (Fig 2). Their mean
follow-up since randomization into BOA was 11 years.
The health related quality of life scores. In compar-
ison with the norm scores of the Dutch population, both
the short-term HR-QoL scores in 1001 patients and the
long-term HR-QoL scores in 123 patients were lower for
all health dimensions and health states, reaching statistical
significance for all health dimensions and health states
except for the mental health score (Table II).
At long-term follow-up, half of the total number of
responders (n  123) had experienced at least one adverse
vascular event (ie, ischemic or bleeding; Fig 3, Table III).
The mean HR-QoL scores after the occurrence of an
adverse vascular event were lower for all health dimensions
and health states compared with the scores of responders
who did not experience an adverse vascular event, reaching
statistical significance for the VAS score and the physical
component summary score (Fig 3). In patients after pri-
Fig 1. Time frame of data collection. HR-QoL, Health-related
quality of life; VE, vascular events.mary bypass occlusion (n  28), a statistically significant dower score for physical functioning (44 vs 58; mean differ-
nce, 14; 95% CI, 1-27; P .030), physical role (35 vs 57;
ean difference, 22; 95% CI, 3-42; P  .023), and emo-
ional role (50 vs 77; mean difference, 27; 95% CI, 7-47; P
.010) were seen in comparison with the scores in pa-
ients with a patent graft (n  61). The scores for pain
59 vs 68; mean difference, 9; 95% CI, 4 to 22; P 
16) and social functioning (68 vs 75; mean difference, 7;
5% CI,6 to 20; P .30) were also lower, but without
eaching statistical significance. The HR-QoL scores in
atients who experienced one or two adverse vascular
vents other than graft failure (n  17) were slightly
ower than the scores in patients who experienced graft
ailure only (n  28), without reaching statistical signif-
cance. Patients with a patent graft and no other adverse
ascular events (n  61) scored lower than the general
utch population for all health dimensions and health
tates, reaching statistical significance for physical function-
ng (58 vs 67; mean difference, 9; 95% CI, 1-18), physical
ole (57 vs 69; mean difference, 12; 95% CI, 2-22), bodily
ain (68 vs 75; mean difference, 7; 95% CI, 1-13), social
unctioning (75 vs 83; mean difference, 8; 95% CI,
-14), and the mean health state (0.68 vs 0.88; mean
ifference, 0.20; 95% CI, 0.14-0.26). Our study did not
ontain enough patients with a major lower limb ampu-
ation (n  11) to allow for reliable comparisons of
R-QoL scores in patients without a major amputation.
Fifty-three responders completed the HR-QoL ques-
ionnaires three times during follow-up (Fig 4). Over time
decrease was seen for all mean HR-QoL scores, except for
odily pain, mental health, and the mental component
ummary score, which remained largely unchanged over
ime. The physical functioning score and the VAS score
ecreased significantly between the last patient visit for
OA and at BOA long-term follow-up (Fig 4). Between
OA inclusion and BOA long-term follow-up, the scores
or general health, physical functioning, physical compo-
ent summary, emotional role, EQ-5D mean health state,
nd VAS decreased significantly (Fig 4).
ISCUSSION
We have studied the change in HR-QoL over a mean
eriod of 11 years in patients with PAD after peripheral
ypass surgery. In comparison with the general population,
atients with PAD have a considerably lower physical HR-
oL, even if they have a patent graft and experienced no
ther adverse vascular events. Over time the physical HR-
oL in PAD patients deteriorated further, while mental
ealth and the perception of pain remained fairly stable.
he occurrence of an adverse vascular event lowered the
hysical HR-QoL even more.
Our findings are in agreement with other studies. The
eripheral Arterial Disease Awareness, Risk, and Treat-
ent: New Resources for Survival (PARTNERS) Program
ound the physical component summary score to be signif-
cantly lower in patients with PAD than in patients without
AD.26 The mental component summary score, however,
id not differ between patients with or without PAD.26
Fig 2. Study design. BOA, Bypass and Oral Anticoagulants or Aspirin; HR-QoL, health-related quality of life.
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Baseline characteristics
Responders
(n  123) N (%)
Nonresponders
(n  42) N (%) RR (95% CI; P value)
Demographic factors
Male 87 (71) 24 (57) 1.2 (0.9-1.6; P  .105)
Mean age at study inclusion 62 (SD  9.2) 67 (SD  10.5) 5.5a (9.1 to 1.8; P  .004)b
Mean age at follow-up 73 (SD  9.1) 78 (SD  10.7) 5.1a (8.8 to 1.4; P  .008)b
Medical history at bypass surgery
Angina pectoris 16 (13) 7 (17) 0.8 (0.4-1.8; P  .554)
Myocardial infarction 14 (11) 6 (14) 0.8 (0.3-1.9; P  .619)
TIA and/or stroke 5 (4) 7 (17) 0.2 (0.1-0.7; P  .007)b
ABI 0.55 (SD  0.23) 0.57 (SD  0.23) 0.02a (0.10 to 0.06; P  .698)
ABI 0.9 117 (95) 39 (93) 1.0 (0.9-1.1; P  .694)
ABI 0.6 65 (53) 24 (57) 0.9 (0.7-1.3; P  .630)
Critical limb ischemia 34 (28) 12 (29) 1.0 (0.6-1.7; P  .908)
Diabetes mellitus 17 (14) 8 (19) 0.7 (0.3-1.6; P  .415)
Hypertension 38 (31) 13 (31) 1.0 (0.6-1.7; P  .994)
Hyperlipidemia 39 (32) 11 (26) 1.2 (0.7-2.1; P  .502)
Smoking 76 (62) 29 (69) 0.9 (0.7-1.1; P  .398)
Vascular intervention 44 (36) 12 (29) 1.3 (0.7-2.1; P  .395)
Trial bypass
Femorocrural/pedal bypass 21 (17) 8 (19) 0.9 (0.4-1.9; P  .772)
Venous bypass 80 (65) 26 (62) 1.1 (0.8-1.4; P  .714)
Trial medication after bypass surgery
Oral anticoagulants 62 (50) 21 (50) 1.0 (0.7-1.4; P  .964)
ABI,Ankle-brachial index;CI, confidence interval;HR-QoL, health-related quality of life;RR, relative risk with 95%CI; SD, standard deviation; TIA, transient
ischemic attack.
aMean difference with corresponding 95% confidence intervals.


















Based on a cohort of n  5356.
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Volume 53, Number 3 van Hattum et al 647orresponding results were found in the Edinburgh Artery
tudy, but only for patients with symptomatic PAD.27 In
atients with asymptomatic PAD the HR-QoL did not
iffer from patients without PAD.27 Moreover, the HR-
oL was found to decrease significantly with an increasing
everity of symptomatic PAD.17,18,21 The largest decre-
ents were seen for physical functioning, social function-
ng, pain, and physical role.17 The scores for mental health
ecreased only marginally despite PAD worsening from
ild claudication to tissue loss.17
To our knowledge, only one other study described the
hanges inHR-QoL in PADpatients after revascularization at
ong-term follow-up.28 The HR-QoL scores significantly im-
roved shortly after successful revascularization, as shown
efore in other studies,29,30 and remained largely unchanged
p to 1 year after revascularization. However, at 4 years after










(23) 60 (24) 7 (1-13)e
(30) 67 (26) 19 (12-26)e
(44) 69 (43) 23 (12-34)e
(28) 75 (28) 8 (1-15)e
(12) — —
(24) 64 (22) 6 (0.2-12)e
(31) 83 (24) 13 (6-20)e
(44) 83 (34) 19 (9-29)e
(22) 76 (17) 4 (1 to 9)
(13) — —
(0.28) 0.88 (0.19)b 0.25 (0.22–0.28)e
(0.26) 0.90 (0.17)c 0.24 (0.21–0.27)e
(0.32) 0.85 (0.21)d 0.29 (0.25–0.33)e
(19) — —
gue scale.
scores of the Dutch population.




n  123 (%)
o event 61 (50)
event: 42 (34)
-Primary bypass occlusion 28 (67)
-Major amputations 1 (2)
-Myocardial infarction 6 (14)
-Ischemic stroke 5 (12)
-Major bleeding 2 (5)
events 14 (11)
3 events 6 (5)Fig 3. Health-related quality of life (HR-QoL) scores per number of
adverse vascular events.95%CI, 95%Confidence interval;EQ-5D, Euro-
QoL 5D mean health state; MCS, mental component summary; PCS,









General health 55 (23) 53
Physical functioning 49 (28) 48
Role physical functioning 38 (43) 46
Bodily pain 59 (28) 67
Physical component summary 37 (11) 38
Vitality 55 (23) 58
Social functioning 65 (30) 70
Role emotional 56 (44) 64
Mental health 68 (22) 72
Mental component summary 48 (12) 50
EQ-5D
Mean health state 0.63 (0.30) 0.63
-Male 0.67 (0.29) 0.66
-Female 0.57 (0.31) 0.56
VAS-score 66 (20) 66
HR-QoL, Health-related quality of life; SD, standard deviation; VAS, visual analo
aComparison of the HR-QoL scores at BOA long-term follow-up with the norm
bBased on a cohort of n  9685.
cBased on a cohort of n  4329.
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revascularization.28 These observed changes inHR-QoL after
revascularization corresponded well with our findings in 53
patients with three consecutive measurements over a mean
period of 11 years. No clear explanation could be found for
the fairly stable scores found for bodily pain andmental health,
whereas the scores for the other dimensions and health states
decreased over time. We assumed that perhaps coping mech-
anisms made the perception of pain become less pronounced
over time and enables to adapt the mental health state to new
conditions.
Not only does the HR-QoL deteriorate over time, but
the HR-QoL also worsens substantially after the occur-
rence of an adverse vascular event. After a bypass occlusion
a patient’s physical health was lower than in patients with a
patent graft, and decreased even more in patients who
experienced an adverse vascular event other than bypass
occlusion. Unfortunately, we were not able to distinguish
the HR-QoL scores between the types of events due to too
few numbers of the respective events. The patients who
participated in our study were derived from theDutch BOA
Fig 4. Health-related quality of life (HR-QoL) scores
Study inclusion, close-out, and long-term follow-up f
Euro-QoL 5Dmean health state; LPV, last patient visit;M
summary; VAS, visual analogue scale; *(*), statistical signStudy.6 In the Dutch BOA Study, the largest differences in nealth dimensions were seen after graft failure and lower
imb amputation in comparison with patients without an
schemic event.3 A symptomatic bypass occlusion or a
econd revascularization significantly lowered a patient’s
ain score and social functioning score. After a lower limb
mputation, the lowest scores were reached in almost all
ealth dimensions, especially in physical functioning, phys-
cal role, and emotional role. This finding is in line with a
tudy that compared the HR-QoL in 130 amputees with
he HR-QoL in 115 controls.31 The amputees had signif-
cantly worse scores for all health dimensions, especially for
hysical health.31 According to these results, limb salvage is
mportant to prevent worsening of a patient’s HR-QoL.
eripheral bypass surgery is able to relieve lower limb
omplaints and avoid amputation in the short term, but did
ot prove to be durable for limb salvage and HR-QoL
cores. To stabilize the HR-QoL in patients with PAD as
ong as possible, atherosclerotic risk management through
ifestyle modifications and drug treatments might be just as
mportant as surgical intervention.
A possible limitation of our study is the relatively small
tch Bypass and Oral Anticoagulants or Aspirin (BOA)
patients.95% CI, 95% Confidence interval; EQ-5D,
mental component summary; PCS, physical component
ce.at Du
or 53
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Volume 53, Number 3 van Hattum et al 649ments of HR-QoL over time. However, at long-term fol-
low-up a cohort of patients at high risk of vascular morbid-
ity and mortality is expected to be small. Although a single
HR-QoL measurement is sufficient to assess the HR-QoL
at that moment in time,28–30 it would have been preferable
to have smaller time intervals at which the HR-QoL was
assessed for a more accurate outline of the course of the
HR-QoL over time. Unfortunately, in a retrospective fol-
low-up, this is not possible. Also, we did not inquire after
other possible causes of walking disability than symptom-
atic PAD, such as trauma or arthritis, which could also
negatively affect the physical health state. Therefore, we
cannot be completely sure that the observed decrease in
physical functioning is caused by the consequences of PAD
only. However, we did find the physical component score
to significantly decrease after a vascular event had occurred
(Fig 3), which makes the deterioration due to PAD more
likely. Lastly, our long-term HR-QoL scores are probably
higher than average due to survival bias, as long-term
survivors probably have a better health state and thus
higher HR-QoL scores compared with those who de-
ceased. Moreover, the 123 responders probably had a
better health state than the 42 nonresponders at long-term
follow-up. Nevertheless, our study is the first to describe
the change in the HR-QoL in patients with PAD over a
mean period of 11 years after infrainguinal bypass surgery.
Further prospective long-term studies in even larger popu-
lations are needed to gain insight in HR-QoL, taking the
various disease states and complications that occur because
of atherosclerosis into account.
CONCLUSIONS
Patients with PAD after peripheral bypass surgery have
a substantially impaired HR-QoL even if their graft is
patent. Over time their HR-QoL deteriorates further,
mainly driven by reduced physical health. A patient’s phys-
ical health worsens further after the occurrence of an ad-
verse vascular event. This underlines the importance of
secondary prevention and optimal health care in PAD
patients to preserve the QOL.
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